Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from H.L. Gomez and co-authors have provided new information about breast cancer
August 7th, 2008
" This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer. Patients and Methods Patients with ErbB2-amplified, locally advanced or metastatic breast cancer previously untreated in the metastatic setting were randomly assigned to one of two lapatinib dose cohorts and received either 1,500 mg once daily or 500 mg twice daily," scientists in Lima, Peru report. "Clinical response was assessed at weeks 8 and 12 and every 12 weeks thereafter. A total of 138 patients were treated with lapatinib for a median of 17.6 weeks. The...
Source: Women's Health Weekly (2008-08-07)
|
